GFP
ABCL icon

Gryphon Financial Partners’s AbCellera Biologics ABCL Stock Holding History

Gryphon Financial Partners’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-12,438
Closed -$62.6K – 333
2025
Q3 		$62.6K Buy
+12,438
New +$54.8K 0.01% 323
2022
Q4 		– Sell
-10,490
Closed -$104K – 199
2022
Q3 		$104K Sell
10,490
-1,850
-15% -$20.3K 0.03% 189
2022
Q2 		$131K Buy
12,340
+1,850
+18% +$15.7K 0.03% 188
2022
Q1 		$102K Buy
+10,490
New +$99.3K 0.02% 194

Other funds holding ABCL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Gryphon Financial Partners's ABCL Position: Q4 2025 in Review

Gryphon Financial Partners sold out of AbCellera Biologics (ABCL) in Q4 2025, closing a stake of 12,438 shares — an estimated $62.6K sold.

Gryphon Financial Partners first reported a position in ABCL in Q1 2022 and held it in 4 quarters. The position peaked at $131K in Q2 2022. 144 funds tracked by Wall St. Rank hold ABCL as of Q4 2025.

  • Gryphon Financial Partners reported no remaining AbCellera Biologics position as of Q4 2025 after selling out during the quarter.
  • Gryphon Financial Partners sold 12,438 AbCellera Biologics shares in Q4 2025, an estimated $62.6K.
  • Gryphon Financial Partners first reported a position in AbCellera Biologics in Q1 2022 and held it in 4 quarters.
  • Gryphon Financial Partners's AbCellera Biologics position peaked at $131K in Q2 2022.
  • 144 funds tracked by Wall St. Rank held AbCellera Biologics as of Q4 2025.

Based on Gryphon Financial Partners's 13F filing for Q4 2025, filed 8 Jan 2026.